Table 2.

Baseline gastric histological grading of the randomised patients

Histological grading (updated Sydney classification)	Eradication (Group HpE) (n = 53)	Placebo (Group Hp+) (n = 51)	p Value
Antral gastritis (%)
0–2	5 (9.6)	11 (22)
3–4	32 (61.5)	24 (48)	0.19
5–6	15 (28.8)	15 (30)
Corpus gastritis (%)
0–2	25 (49)	22 (44.9)
3–4	19 (37.3)	17 (34.7)	0.67
5–6	7 (13.7)	10 (20.4)
Antral atrophy (%)
0	46 (88.5)	40 (80)
1	4 (7.7)	7 (14)	0.53
2	2 (3.8)	2 (4)
3	0 (0)	1 (2)
Corpus atrophy (%)
0	50 (98)	47 (95.9)
1	1 (2)	2 (4.1)	0.49
2	0 (0)	0 (0)
3	0 (0)	0 (0)
Antral intestinal metaplasia (%)
0	38 (73.1)	36 (72)
1	8 (15.4)	8 (16)	0.78
2	6 (11.5)	5 (10)
3	0 (0)	1 (2)
Corpus intestinal metaplasia (%)
0	47 (92.2)	48 (98)
1	2 (3.9)	1 (2)	0.32
2	2 (3.9)	0 (0)
3	0 (0)	0 (0)